Biogen shares fell 3.4% after earnings, despite reported revenue growth, as the growth headline relies partly on the Appellis acquisition and management still expects a return to top-line growth only in 2026. Investors may also be weighing the company’s dependence on future pipeline readouts, several of which remain weeks to months away.
- Total revenue grew 11% year over year, with management saying the increase was significantly helped by the Appellis acquisition.
- Biogen’s growth portfolio generated $1.26 billion, up 50% year over year; management said it now represents almost two-thirds of core pharmaceutical revenue in the quarter.
- SYFOVRE and Empaveli combined for $243 million, up 37% year over year. Biogen expects $250 million of run-rate synergies by the end of 2027 and said operating-level acquisition dilution is already close to negligible.
- Management expects to return to top-line growth in 2026, while noting the legacy MS portfolio remains resilient.
- The outlook depends in part on upcoming clinical results: management expects multiple Phase 3 readouts in the next 18 months, including in lupus and AMR.
Community Discussion